Avetix

🎉 1 Year at Avetix: Katie Soper! 🎉 Katie joined us a year ago and not only has she been building our Cyber division, she has been driving the branding for AvetixCyber every step of the way. In the last year alone, she has released over 50 podcasts and integrated herself into some of the most niche communities across the cyber landscape. She's also built partnerships with incredible VCs & investors, and supported their portfolio founders in finding exceptional Sales & GTM talent. Thanks for everything over the past year, Katie - here’s to the next one!

📢 𝗖𝗔𝗟𝗟𝗜𝗡𝗚 𝗟𝗘𝗘𝗗𝗦 𝟯𝟲𝟬 𝗥𝗘𝗖𝗥𝗨𝗜𝗧𝗘𝗥𝗦!! 📢 🚀 Looking for an exciting new challenge to start the New Year!! ❌ Bored of your current place of work? ❌ Fed up with a rubbish culture? ❌ Working for managers who dictate instead of leading from the front? 📢 𝑳𝒆𝒆𝒅𝒔-𝒃𝒂𝒔𝒆𝒅 360 𝒓𝒆𝒄𝒓𝒖𝒊𝒕𝒆𝒓𝒔… 𝒊𝒕 𝒅𝒐𝒆𝒔𝒏’𝒕 𝒉𝒂𝒗𝒆 𝒕𝒐 𝒃𝒆 𝒕𝒉𝒂𝒕 𝒘𝒂𝒚. ✅ Want to work in an amazing culture where you’re surrounded by top performers? ✅ Want leaders who bill, not just talk? ✅ Want true flexibility to work with clients across the Americas, EMEA, and APAC? ✅ Want a workplace that actually encourages personal health, well-being, and growth? At AvetixCyber, we’re scaling fast - and we’re hiring people who want to be part of something bigger, something better, and something that actually delivers on the things other companies only claim. If you’re ready for a culture that lifts you up, leadership that leads by example, and global opportunities without limits… 🔥 Let’s talk. Avetix is also hiring aggressively across our Avetix Engineering and Avetix Bio Business Units. For more information contact myself or Mathew Turek for everything AvetixCyber. For Avetix Engineering it's Thomas Hall and Joe Worth. And it's Max Brennan, MSc and Tom Weir for everything Avetix Bio! #avetix #hiring #recruitmentsuperstars #cyberrecruitment

2026 𝐢𝐬 𝐠𝐨𝐢𝐧𝐠 𝐭𝐨 𝐛𝐞 𝐚 𝐛𝐢𝐠 𝐲𝐞𝐚𝐫 𝐟𝐨𝐫 𝐀𝐯𝐞𝐭𝐢𝐱 𝐚𝐧𝐝 𝐰𝐞’𝐫𝐞 𝐇𝐈𝐑𝐈𝐍𝐆. 💜 We’ve already got some serious hitters signed to join us in the next few months (people other firms would kill to land)… and we’re still speaking to a handful more. Because here’s the reality 👇 𝐖𝐡𝐲 𝐞𝐯𝐞𝐧 𝐭𝐡𝐢𝐧𝐤 𝐚𝐛𝐨𝐮𝐭 𝐥𝐞𝐚𝐯𝐢𝐧𝐠 𝐰𝐡𝐞𝐫𝐞 𝐲𝐨𝐮 𝐚𝐫𝐞? You might recognise some of this: 🟣 You’re surrounded by grads and average performers, and you’re the one propping the numbers up. 🟣 More pressure, more KPIs, more “loyalty” chat… but not more development. 🟣 “New” non-competes thrown at you for tiny pay rises. 🟣 Sat in an industry on your own with little to no real support. 🟣 Great year on the board… but the only plan is “beat this month’s target” and repeat. Comfortable? Yes. But if you want to actually 𝘱𝘳𝘰𝘨𝘳𝘦𝘴𝘴, you’re going to have to step outside that comfort zone. 𝐖𝐡𝐲 𝐀𝐯𝐞𝐭𝐢𝐱? 💜 𝐇𝐢𝐠𝐡𝐞𝐬𝐭 𝐝𝐞𝐧𝐬𝐢𝐭𝐲 𝐨𝐟 𝐭𝐨𝐩 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐞𝐫𝐬 𝐲𝐨𝐮’𝐥𝐥 𝐟𝐢𝐧𝐝 We’re 22 people with: ▫️ Multiple £1𝐌+ 𝐛𝐢𝐥𝐥𝐞𝐫𝐬 ▫️ 5x £500𝐤+ 𝐛𝐢𝐥𝐥𝐞𝐫𝐬 ▫️ The vast majority at £300𝐤+ Find out why we're continually attracting the best. 🏆 𝐖𝐞’𝐫𝐞 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐰𝐢𝐧 4 business units - 𝐓𝐈𝐂, 𝐁𝐢𝐨, 𝐂𝐲𝐛𝐞𝐫, 𝐅𝐮𝐭𝐮𝐫𝐞 𝐌𝐨𝐛𝐢𝐥𝐢𝐭𝐲 - all with clear plans to be the best in their sector. TIC is already operating at that level. Bio, FM & Cyber have the proposition, clients and people to follow the same path. 💜 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐭𝐡𝐚𝐭 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐦𝐞𝐚𝐧𝐬 𝐬𝐨𝐦𝐞𝐭𝐡𝐢𝐧𝐠 No egos. Underdog mentality. Freedom to flourish. Dream Big. People doing Ironmans, marathons, building brands and teams and a business that backs them to do it. ✈️ 𝐓𝐫𝐚𝐯𝐞𝐥 𝐛𝐚𝐤𝐞𝐝 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐣𝐨𝐛 We don’t talk about travel as a “perk”, it’s part of how we operate. 2026 already has people booked for San Francisco, Las Vegas, Austin, Boston, San Diego and trips across Europe: in-person with the clients that matter. Short story: 𝐢𝐟 𝐲𝐨𝐮’𝐫𝐞 𝐛𝐢𝐥𝐥𝐢𝐧𝐠 𝐰𝐞𝐥𝐥, 𝐲𝐨𝐮 𝐍𝐄𝐄𝐃 𝐭𝐨 𝐭𝐚𝐥𝐤 𝐭𝐨 𝐮𝐬. Worst case: you confirm you’re already in the right place. Best case: 2026 becomes the year everything steps up a level. Drop me a message. No pressure, just a chat about what we’re all about. 💜

Last night marked a momentous moment in the journey for Avetix Bio! We hosted the hottest party on the Jefferies convention calendar. Nobel prize winners, Public CEO's and IPO geniuses. We spoke all topics bioTech, Life and whats next. Watch this space!

Our very first Tales of TIC newsletter is live on the Avetix Engineering page! This one is for our amazing TIC community. If you want to read about... - What’s shaping the TIC industry from Q3 results - Major acquisitions  - Standout partnerships - As well as this get links to listen to this month’s podcast guests ...then head over to the newsletter below! And don't forget to subscribe to catch the next one! 👏

𝐖𝐡𝐨𝐨𝐩 𝐰𝐡𝐨𝐨𝐩! 𝐓𝐡𝐞 𝐈𝐏𝐎 𝐰𝐢𝐧𝐝𝐨𝐰 𝐢𝐬 (𝐚𝐥𝐦𝐨𝐬𝐭) 𝐛𝐚𝐜𝐤 𝐨𝐩𝐞𝐧… (or maybe I’m jumping the gun just a little 🤣) 🔥 𝐎𝐧𝐥𝐲 𝐭𝐡𝐞 𝐬𝐞𝐜𝐨𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐏𝐎 𝐬𝐢𝐧𝐜𝐞 𝐅𝐞𝐛𝐫𝐮𝐚𝐫𝐲, following LB Pharmaceuticals Inc’s $285M raise last month. The thought of just two IPOs in eight months is crazy. It says everything about how selective investors have been. So when a company does break through, 𝘪𝘵’𝘴 𝘸𝘰𝘳𝘵𝘩 𝘱𝘢𝘺𝘪𝘯𝘨 𝘢𝘵𝘵𝘦𝘯𝘵𝘪𝘰𝘯. MapLight Therapeutics, Inc. have gone public! Raising $250𝐌 to fund its programs in schizophrenia and Alzheimer’s psychosis. Their play? 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐧𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞, targeting specific neural circuits behind psychiatric and neurological disorders. 🧠 They’re going after some of the hardest problems in CNS by diving deeper into the brain’s circuitry, not just throwing another symptom-management drug at it. It’s a brave space to play in and the market’s rewarding them for being bold. The track record in CNS drug development is brutal. But this kind of conviction and investor backing might just signal that the appetite for 𝐛𝐨𝐥𝐝 𝐧𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐛𝐞𝐭𝐬 is creeping back. Frankly, whether or not the IPO window 𝘳𝘦𝘢𝘭𝘭𝘺 reopens will depend on how MapLight and LB perform over the next few months… right in time for #JPM. 👀 Stay tuned! We might just have some insight into both IPOs! We may be welcoming Heather Turner from LB and Vishwas Setia from MapLight to The BioHub Podcast soon 😉 Chris Kroeger, MD | James Lillie | Anatol Kreitzer | Erin Pennock | Jonathan Gillis | Kris Hanson #Biotech #IPO #Neuroscience #CNS #Leadership #Innovation

💥 𝐁𝐢𝐠 𝐩𝐡𝐚𝐫𝐦𝐚’𝐬 𝐩𝐮𝐥𝐥𝐢𝐧𝐠 𝐛𝐚𝐜𝐤 𝐟𝐫𝐨𝐦 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲, 𝐛𝐮𝐭 𝐭𝐡𝐢𝐬 𝐢𝐬𝐧’𝐭 𝐭𝐡𝐞 𝐞𝐧𝐝. In the last few weeks alone 👇 🔹 Takeda exited the space, taking a ~$390M hit. 🔹 Novo Nordisk shut its cell therapy unit (250 jobs gone). 🔹 Galapagos wound theirs down after a failed sale (365 roles affected). Three exits in a month. Brutal optics… but maybe a 𝘩𝘦𝘢𝘭𝘵𝘩𝘺 𝘳𝘦𝘴𝘦𝘵. The science works - 𝐭𝐡𝐞 𝐦𝐚𝐭𝐡 𝐝𝐨𝐞𝐬𝐧’𝐭 (𝐲𝐞𝐭). Manufacturing, COGS, and scale are still the bottleneck. And right now, capital’s chasing what’s faster and cleaner to produce (GLP-1s, ADCs, small molecules). But the infrastructure, tech, and people built in the last decade don’t just disappear. They’ll be the foundation for 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 2.0. Smarter, leaner, and built around 𝘣𝘢𝘯𝘬𝘢𝘣𝘭𝘦 𝘦𝘤𝘰𝘯𝘰𝘮𝘪𝘤𝘴, not just beautiful science. 🚀 𝐍𝐨𝐭 𝐭𝐡𝐞 𝐞𝐧𝐝 𝐨𝐟 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲. 𝐉𝐮𝐬𝐭 𝐭𝐡𝐞 𝐞𝐧𝐝 𝐨𝐟 𝐯𝐞𝐫𝐬𝐢𝐨𝐧 1.0. ⚙️ Avetix | Avetix Bio